To request a free sample copy of this report, please complete the form below.
What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

logos logos logos logos logos
Analyst Support
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Heparin Market size was valued at USD 7.48 billion in 2022 and is poised to grow from USD 7.68 billion in 2023 to USD 9.51 billion by 2031, at a CAGR of 2.7% during the forecast period (2024-2031).

Details about each competitor are included in the heparin market competitive landscape. Included data includes an overview of the company, financials, revenue generated, market potential, investments in R&D, new market initiatives, presence, production sites and facilities, production capacities, company strengths and weaknesses, product launches and application dominance. Only the companies' focus on the heparin industry is mentioned in the data points above. 'Pfizer Inc. (United States)', 'Sanofi S.A. (France)', 'Leo Pharma A/S (Denmark)', 'Fresenius Kabi AG (Germany)', 'Aspen Holdings (South Africa)', 'Teva Pharmaceutical Industries Ltd. (Israel)', 'Dr. Reddy's Laboratories Ltd. (India)', 'B. Braun Melsungen AG (Germany)', 'LEO Pharma A/S (Denmark)', 'Baxter International Inc. (United States)', 'Shanghai Institute of Biological Products (China)', 'Nanjing King-friend Biochemical Pharmaceutical (China)', 'Changzhou Qianhong Bio-pharma (China)', 'Opocrin S.p.A. (Italy)', 'Nantong Pharmaceutical (China)', 'Celsus Laboratories Inc. (United States)', 'Hebei Changshan Biochemical Pharmaceutical (China)', 'Bioiberica S.A.U. (Spain)', 'Dongying Tiandong Pharmaceutical (China)', 'Shenzhen Hepalink Pharmaceutical Co., Ltd. (China)', 'Pharma Action GmbH (Germany)'

The need for heparin is increasing as coagulation diseases like venous thromboembolism (VTE), which includes both deep vein thrombosis and pulmonary embolism, are becoming more common. VTE, which includes pulmonary embolism and deep vein thrombosis, kills over 1.2 million individuals every year. Additionally, VTE is the biggest cause of death in Europe, outpacing AIDS, breast and prostate cancer, as well as traffic accidents taken together. Additionally, the market is growing as a result of an increase in hypertension instances brought on by an unhealthy lifestyle. Heart attacks and strokes, which are on the rise, will open up new commercial prospects. According to the American Heart Association's (AHA) heart disease and Stroke Statistics, atrial fibrillation has an impact on Americans total 5.3 million. The market may be significantly impacted by rising patient demand for heparin.

With the increasing use of heparin and other anticoagulant therapies, there is a growing need for effective reversal agents to counteract their anticoagulant effects in emergency situations or during surgery. Research and development efforts are underway to develop novel anticoagulant reversal agents, providing an additional growth avenue for the heparin market.

In 2022, North America dominated the market and contributed 38.97% of total revenue. The increase in cardiovascular diseases and injuries is to blame for this. In addition, rising levels of healthcare spending and rising patient awareness in this region are the other variables that contribute to the high share. According to the CDC, heart disease will be one of the leading causes of death in the United States in 2022, killing 659,000 people a year, or 1 in every 4 fatalities.

Feedback From Our Clients

Global Heparin Market

Product ID: SQMIG35H2166